CN100369908C - 紫杉烷衍生物 - Google Patents
紫杉烷衍生物 Download PDFInfo
- Publication number
- CN100369908C CN100369908C CNB988092395A CN98809239A CN100369908C CN 100369908 C CN100369908 C CN 100369908C CN B988092395 A CNB988092395 A CN B988092395A CN 98809239 A CN98809239 A CN 98809239A CN 100369908 C CN100369908 C CN 100369908C
- Authority
- CN
- China
- Prior art keywords
- compound
- alkyl
- carbonyl
- amino
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 title claims abstract description 27
- -1 piperazino Chemical group 0.000 claims abstract description 63
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 13
- 125000000000 cycloalkoxy group Chemical group 0.000 claims abstract description 4
- 125000002541 furyl group Chemical group 0.000 claims abstract description 3
- 125000004076 pyridyl group Chemical group 0.000 claims abstract description 3
- 125000001544 thienyl group Chemical group 0.000 claims abstract description 3
- 150000003839 salts Chemical class 0.000 claims description 15
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- AVRDNHXYNWWMGN-UHFFFAOYSA-N C(C)(C)OOCC(C)(C)C Chemical group C(C)(C)OOCC(C)(C)C AVRDNHXYNWWMGN-UHFFFAOYSA-N 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 78
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 12
- 230000000259 anti-tumor effect Effects 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 4
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000004665 trialkylsilyl group Chemical group 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 22
- 238000005160 1H NMR spectroscopy Methods 0.000 description 17
- 239000002585 base Substances 0.000 description 15
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 12
- 229930012538 Paclitaxel Natural products 0.000 description 11
- 229960001592 paclitaxel Drugs 0.000 description 11
- 239000000203 mixture Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 238000011088 calibration curve Methods 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 2
- OFTKFKYVSBNYEC-UHFFFAOYSA-N 2-furoyl chloride Chemical compound ClC(=O)C1=CC=CO1 OFTKFKYVSBNYEC-UHFFFAOYSA-N 0.000 description 2
- IHCCAYCGZOLTEU-UHFFFAOYSA-N 3-furoic acid Chemical compound OC(=O)C=1C=COC=1 IHCCAYCGZOLTEU-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- NFFRARWFAPFSSE-UHFFFAOYSA-N CCCCCOC(OC)=O.COC(O)=O Chemical class CCCCCOC(OC)=O.COC(O)=O NFFRARWFAPFSSE-UHFFFAOYSA-N 0.000 description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
- OIFBSDVPJOWBCH-UHFFFAOYSA-N Diethyl carbonate Chemical compound CCOC(=O)OCC OIFBSDVPJOWBCH-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 241000202349 Taxus brevifolia Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000008065 acid anhydrides Chemical class 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 229940034982 antineoplastic agent Drugs 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 150000003851 azoles Chemical class 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 238000010025 steaming Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- BMUDPLZKKRQECS-UHFFFAOYSA-K 3-[18-(2-carboxyethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethylporphyrin-21,24-diid-2-yl]propanoic acid iron(3+) hydroxide Chemical compound [OH-].[Fe+3].[N-]1C2=C(C)C(CCC(O)=O)=C1C=C([N-]1)C(CCC(O)=O)=C(C)C1=CC(C(C)=C1C=C)=NC1=CC(C(C)=C1C=C)=NC1=C2 BMUDPLZKKRQECS-UHFFFAOYSA-K 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- WMKMMTNVPCOKKF-UHFFFAOYSA-N C1(=CC=CC=C1)N1CCCCC1.C=N.C=N.C=N.C=N Chemical class C1(=CC=CC=C1)N1CCCCC1.C=N.C=N.C=N.C=N WMKMMTNVPCOKKF-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 241001116498 Taxus baccata Species 0.000 description 1
- 240000006474 Theobroma bicolor Species 0.000 description 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- FGDQGIKMWOAFIK-UHFFFAOYSA-N acetonitrile;phosphoric acid Chemical compound CC#N.OP(O)(O)=O FGDQGIKMWOAFIK-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- BMLSTPRTEKLIPM-UHFFFAOYSA-I calcium;potassium;disodium;hydrogen carbonate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].OC([O-])=O BMLSTPRTEKLIPM-UHFFFAOYSA-I 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 230000006315 carbonylation Effects 0.000 description 1
- 238000005810 carbonylation reaction Methods 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 description 1
- ZFQCRLNKHHXELH-UHFFFAOYSA-N cyclopentyl carbonochloridate Chemical compound ClC(=O)OC1CCCC1 ZFQCRLNKHHXELH-UHFFFAOYSA-N 0.000 description 1
- 125000001887 cyclopentyloxy group Chemical group C1(CCCC1)O* 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- YWGHUJQYGPDNKT-UHFFFAOYSA-N hexanoyl chloride Chemical compound CCCCCC(Cl)=O YWGHUJQYGPDNKT-UHFFFAOYSA-N 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- MSYBLBLAMDYKKZ-UHFFFAOYSA-N hydron;pyridine-3-carbonyl chloride;chloride Chemical compound Cl.ClC(=O)C1=CC=CN=C1 MSYBLBLAMDYKKZ-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- IVRIRQXJSNCSPQ-UHFFFAOYSA-N propan-2-yl carbonochloridate Chemical compound CC(C)OC(Cl)=O IVRIRQXJSNCSPQ-UHFFFAOYSA-N 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229960004016 sucrose syrup Drugs 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
- C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/108—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epoxy Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
本发明涉及式(1)所示的紫杉烷衍生物:其中,A代表取代的哌嗪-1-基或哌啶子基,X代表烷基、吡啶基、噻吩基、呋喃基、环烷氧基等,Y代表H或三烷基甲硅烷基,本发明还涉及含有式(1)紫杉烷衍生物的药物。这些化合物在水中具有很高的溶解度,并且具有优良的抗肿瘤活性。
Description
技术领域
本发明涉及在水中具有优良溶解性的紫杉烷(taxane)衍生物,和含有所述紫杉烷衍生物的药物。
背景技术
下式(i)所代表的紫杉醇(注册商标)(i)
是从太平洋紫杉树短叶红豆杉(Taxus brevifolia)的树皮中提取的双萜类化合物,Wall等人在1971年首先分离出该化合物并确定了其结构(《美国化学会杂志》(J.Am.Chem.Soc.),93,2325,1971)。据报道其表现出很强的抗卵巢癌和乳腺癌的效力(《国际医学纪事》(Ann.int.Med.)111,273,1989)。
然而,因为紫杉醇仅少量地溶于水,因此将其配制成注射剂需要特殊溶剂。所以紫杉醇所伴随的问题是,难以将其制成注射剂,并且所用溶剂可能会引发副作用。
近几年来,为了开发出紫杉醇的水溶性衍生物,人们已经作了大量工作(Nicolaou等人,《自然》(Nature),364,464,1993)。然而,到目前为止,没有发现任何具有令人满意特性的衍生物。
因此,本发明的目的是,提供具有改善了的水溶性和高抗肿瘤活性的紫杉醇新衍生物。
本发明的公开
考虑到前述情况,本发明者们已经进行了广泛研究。结果发现,下面式(1)所代表的紫杉烷(紫杉醇骨架的俗称)衍生物具有水溶性和抗肿瘤活性,其水溶性和抗肿瘤活性都比紫杉醇高很多,因此可以用作药物,这样就完成了本发明。
因此,本发明提供了下述式(1)所示的紫杉烷衍生物或其盐:
其中,A代表(其中R1代表氢原子、取代或未取代的烷基或苄氧羰基),或者A代表(其中R2代表氨基、单-烷基氨基或二-烷基氨基或环状氨基);X代表烷基、吡啶基、噻吩基、呋喃基、环烷氧基、异丙氧基、新戊氧基或叔戊氧基;Y代表氢原子或三烷基甲硅烷基;Ac代表乙酰基;Bz代表苯甲酰基;且Ph代表苯基。
此外,本发明还提供了含有式(1)所示紫杉烷衍生物或其盐作为活性组分的药物。
本发明还提供了含有式(1)所示紫杉烷衍生物或其盐作为活性组分的抗肿瘤剂。
本发明还提供了含有式(1)所示紫杉烷衍生物或其盐和可药用载体的药物组合物。
本发明还提供了式(1)所示紫杉烷衍生物或其盐作为药物的应用。
本发明还提供了式(1)所示紫杉烷衍生物或其盐作为抗肿瘤剂的应用。
本发明还提供了治疗肿瘤的方法,包括将有效量的式(1)所示紫杉烷衍生物或其盐对肿瘤患者给药。
实施本发明的最佳方式
本发明紫杉烷衍生物由式(1)表示。在A所代表的基团中的哌嗪基上,由R1代表的作为取代基的烷基可以是具有1-10个碳原子的烷基,其实例包括甲基、乙基、正丙基、异丙基、正丁基、异丁基、仲丁基、叔丁基、正戊基、正己基、正庚基、正壬基和正癸基。在这些烷基中,优选具有1-6个碳原子、尤其是1-4个碳原子的烷基,更优选甲基和乙基。该烷基的取代基的实例有一烷基氨基羰基和二烷基氨基羰基。可提及C1-6烷基氨基羰基作为更优选的一烷基氨基羰基,可提及二(C1-5烷基)氨基羰基作为更优选的二烷基氨基羰基。
在A代表的基团中的哌啶子基上,作为取代基R2代表的一烷基氨基或二烷基氨基上的烷基部分的实例,可提及的有,类似于上述R1所代表的烷基的实例的烷基,其中优选甲基、乙基、正丙基和异丙基。R2代表的环氨基的实例包括吡咯烷-1-基、哌啶子基和吗啉代。
在A代表的基团中,特别优选的实例包括二烷基氨基哌啶子基、哌啶子基哌啶子基、吡咯烷-1-基哌啶子基、吗啉代哌啶子基和N-烷基哌嗪-1-基。
作为由X代表的烷基,可提及的有,类似于上述R1所代表的烷基的实例的烷基,其中更优选C1-6烷基。作为环烷氧基,优选C4-6环烷氧基,更优选环戊氧基和环己氧基。
Y代表的基团是氢原子或三烷基甲硅烷基,其中三烷基甲硅烷基的实例包括三(C1-6烷基)甲硅烷基。作为Y,氢原子是特别优选的。
本发明式(1)紫杉烷衍生物的盐的实例有可药用盐,例如阴离子盐如盐酸盐、氢碘酸盐、酒石酸盐、乙酸盐、甲磺酸盐、马来酸盐、琥珀酸盐和戊二酸盐以及与氨基酸如精氨酸、赖氨酸或丙氨酸形成的盐。此外,本发明紫杉烷衍生物及其盐也可以以水合物的形式存在。其水合物也包括在本发明范围内。
例如,本发明式(1)紫杉烷衍生物可依据下述反应路线制得。
其中,A、Ac、Bz和Ph的定义同上;R3代表氢原子、烷氧基羰基或苄氧基羰基;R4和R5分别代表氢原子、烷基、卤代烷基或烷氧基苯基,条件是,R4和R5不能同时代表氢原子,或者当R4或R5之一代表卤代烷基时,另一个是氢原子;和Y’代表三烷基甲硅烷基。
具体来说,本发明式(1)紫杉烷衍生物是这样制得的:以已知化合物10-去乙酰浆果赤霉素III(2)作为原料,(3)用三烷基甲硅烷基将其7-羟基保护,(4)把水溶性-赋予基团A引入到10-羟基上,(5)将13-羟基唑烷羧基化,(6)把7-羟基脱保护,和把环打开,然后把-COX引入到氨基上。
10-去乙酰浆果赤霉素III上的7-羟基的保护可依据已知方式进行,更具体来说,在吡啶中用三烷基氯硅烷进行处理。作为保护基,三烷基甲硅烷基是优选的,更优选三(C1-6烷基)甲硅烷基,特别优选三乙基甲硅烷基。
然后将化合物(3)上的10-羟基酰化,引入能赋予水溶性的侧链(A-)。
酰化方法的实例可包括,在适当碱存在下使用上述例举的酸衍生物的方法,和使用偶合试剂的方法。
适用于上述酰化反应的酰化剂的实例有酰氯、酸酐和羧酸酯,以及等同于这些酰化剂的衍生物。
作为引入基团(A-)的具体方法,例如,4-二甲基氨基哌啶子基羰基化作用可通过在适当碱(例如正丁基锂)存在下、同时使用溶剂如THF、用4-二甲基氨基哌啶子基碳酰氯进行处理而实现。
然后将13-羟基唑烷羧基化,以获得化合物(5)。唑烷羧基化可通过例如将唑烷甲酸衍生物例如N-苄氧基羰基(Cbz)-2,2-二甲基-4-苯基唑烷甲酸、DCC、二甲氨基吡啶(DMAP)等与化合物(4)反应来进行。
接下来,可通过用酸在溶剂例如乙醇中处理所得化合物(5)来打开唑烷的环,由此脱保护(除去TES),然后在钯-碳存在下进行催化还原,由此可获得化合物(6)。
可通过将化合物(6)上的氨基酰化来将其转化成本发明化合物(1)。所述酰化可在偶合剂例如碱存在下用相应的酰卤、酸酐等来进行。
本发明紫杉烷衍生物(1)在测试(测试2)中被证实具有优良抗肿瘤活性,其中所述测试是使用抗KB细胞的生长抑制效果作为指数来进行的。
因为本发明紫杉烷衍生物(1)及其盐在水中具有很高的溶解度(是紫杉醇的1000倍或更高),所以它们无需使用任何特殊溶剂而可用于药物例如注射剂。作为药物制剂,注射剂例如静脉内注射剂或肌内注射剂是优选的。除了这种制剂以外,它们还可以配制成液体制剂例如吸入剂、糖浆剂或乳剂;固体制剂例如片剂、胶囊或颗粒剂;或外用制剂例如软膏剂或栓剂。
如果需要,这些制剂一般含有常用添加剂例如溶解助剂、稳定剂、湿润剂、乳化剂、吸收增强剂和表面活性剂。这些载体的实例有注射用蒸馏水、林格注射液、葡萄糖、蔗糖糖浆、明胶、食用油、可可脂、硬脂酸镁和滑石粉。
紫杉烷衍生物(1)在上述各种药物制剂中的含量随药物制剂所给药的病人的症状、剂型等因素的不同而不同。然而,每单位剂型中其含量一般为,在注射剂中是约0.5-100mg,在口服制剂中是约5-1000mg,在栓剂中是约5-1000mg。此外,具有上述剂型的该药物的日剂量将随每个患者的症状、体重、年龄、性别等因素的不同而不同,而不能一概而论。尽管如此,每个成人的日剂量一般为约0.1-50mg/kg,优选约1-20mg/kg。优选将该剂量以单次剂量给药或者以分剂量每日给药2-4次。
下面将通过实施例更详细地描述本发明。然而,应当理解的是本发明并不限于这些实施例。
实施例1
13-O-(3-苄氧羰基-2,2-二甲基-4-苯基-5-唑烷羰基)-10-O-(4-甲基哌嗪基羰基)-7-O-三乙基甲硅烷基-10-去乙酰浆果赤霉素III(化合物a)
将10-O-(4-甲基哌嗪-1-基羰基)-7-O-三乙基甲硅烷基-10-去乙酰浆果赤霉素III(240mg,0.31mmol)溶于甲苯,然后加入3-苄氧羰基-2,2-二甲基-4-苯基-5-唑烷甲酸(325mg,0.91mmol)、DCC(206mg,1.0mmol)和DMAP(12mg)。将所得混合物在室温搅拌3小时。把反应混合物过滤。将滤液浓缩后,用饱和碳酸氢钠水溶液洗涤残余物,并用氯仿萃取。用无水硫酸镁干燥有机层,将溶剂减压蒸去,通过硅胶柱色谱纯化残余物(氯仿-甲醇混合溶剂[93∶7]),从而获得了本标题化合物(309mg,89%)。
1H-NMR(CDCl3)δ:0.56(m,6H),0.90(t,J=8Hz,9H),1.17(s,3H),1.18(s,3H),1.63(s,3H),1.74(s,3H),1.80(s,3H),1.88(m,1H,C6-H),1.90(s,3H)),2.08(s,3H),2.14(d,J=10Hz,2H),2.25-2.72(m,5H),2.37(s,3H),3.35-3.75(m,4H),3.78(d,J=7Hz,1H,C3-H),4.09(d,J=8Hz,1H,C20-H),4.23(d,J=8Hz,1H,C20-H),4.43(dd,J=10,7Hz,1H,C7-H),4.49(d,J=5Hz,1H),4.82-5.16(m,2H),4.86(d,J=8Hz,1H,C5-H),5.21(s,1H),5.63(d,J=7Hz,1H,C2-H),6.21(t,J=8Hz,1H,C13-H),6.36(s,1H,C10-H),6.74(br,1H),7.08-7.33(m,9H),7.46(t,J=8Hz,2H),7.60(t,J=7Hz,1H),8.02(d,J=7Hz,2H).
实施例2
13-O-[3-(2-呋喃甲酰氨基)-2-羟基-3-苯基丙酰基]-10-O-(4-甲基哌嗪-1-基羰基)-10-去乙酰浆果赤霉素III(化合物b)
将实施例1的化合物a(43mg,0.04mmol)溶于乙醇(4ml),然后加入0.1N的盐酸(4ml)。把所得混合物在室温搅拌17小时。将溶剂减压蒸去。把饱和碳酸氢钠水溶液加到残余物中进行洗涤,然后用氯仿萃取。用无水硫酸镁干燥有机层,然后减压蒸馏以除去溶剂。将甲醇(5ml)、水(0.5ml)和10%钯/碳(20mg)加到残余物中,然后把所得混合物在氢气气氛下于常温和常压下搅拌4小时。反应混合物通过硅藻土过滤后,把滤液浓缩,将二氯甲烷(10ml)加到所得残余物中以将其溶解。把2-呋喃甲酰氯(4mg,0.03mmol)和三乙胺(0.03mmol)加到所得溶液中,然后在冰浴中搅拌2小时。然后用饱和碳酸氢钠水溶液洗涤该反应混合物,用氯仿萃取。用无水硫酸镁干燥有机层,将溶剂减压蒸去,通过硅胶柱色谱纯化残余物(氯仿-甲醇混合溶剂[19∶1])。通过反相高效液相色谱法进一步纯化(洗脱剂:10mM磷酸二氢钾-乙腈[1∶2]),由此从而获得了本标题化合物(25mg,72%)。
1H-NMR(CDCl3)δ:1.11(s,3H),1.22(s,3H),1.66(s,3H),1.81(s,3H),1.85(m,1H,C6-H),2.24-2.29(m,2H,C14-H),2.35(s,6H),2.43-2.65(m,5H),3.09(s,1H),3.37-3.75(m,4H),3.77(d,J=7Hz,1H,C3-H),4.18(d,J=8Hz,1H,C20H),4.27(d,J=8Hz,1H,C20-H),4.41(m,1H,C7-H),4.75(d,J=2Hz,1H,C2′-H),4.93(d,J=8Hz,1H,C5-H),5.64(d,J=7Hz,1H,C2-H),5.72(dd,J=9,2Hz,1H,C3′-H),6.22(t,J=8Hz,1H,C13-H),6.23(s,1H,C10-H),6.45(dd,J=3,2Hz,1H),7.00(d,J=4Hz,1H),7.14(d,J=9Hz,1H,NH),7.31-7.48(m,6H),7.52(t,J=8Hz,2H),7.61(t,J=8Hz,1H),8.11(d,J=7Hz,2H).
SI-MS m/z:929[M+H]+
实施例3
13-O-[3-(2-噻吩甲酰氨基)-2-羟基-3-苯基丙酰基]-10-O-(4-甲基哌嗪-1-基羰基)-10-去乙酰浆果赤霉素III(化合物c)
使用实施例1的化合物a(37mg,0.03mmol)和2-噻吩甲酰氯(4mg,0.03mmol),如实施例2所述进行反应和后处理,从而获得了本标题化合物(8mg,26%)。
1H-NMR(CDCl3)δ:1.05(s,3H),1.16(s,3H),1.61(s,3H),1.76(s,3H),1.81(m,1H,C6-H),2.07-2.27(m,2H,C14-H),2.31(s,3H),2.39(s,3H),2.38-2.75(m,5H),2.97(s,1H),3.38-3.80(m,4H),3.71(d,J=7Hz,1H,C3-H),4.13(d,J=8Hz,1H,C20-H),4.22(d,J=8Hz,1H,C20-H),4.35(m,1H,C7-H),4.72(d,J=2Hz,1H,C2′-H),4.88(d,J=10Hz,1H,C5-H),5.59(d,J=7Hz,1H,C2-H),5.70(dd,J=9,2Hz,1H,C3′-H),6.15(t,J=8Hz,1H,C13-H),6.18(s,1H,C10-H),6.84(d,J=8Hz,1H,NH),7.00(m,1H),7.28-7.41(m,7H),7.64(t,J=7Hz,2H),7.55(t,J=7Hz,1H),8.06(d,J=8Hz,2H).
SI-MS m/z:944[M+H]+
实施例4
13-O-[3-异烟酰氨基-2-羟基-3-苯基丙酰基]-10-O-(4-甲基哌嗪-1-基羰基)-10-去乙酰浆果赤霉素III(化合物d)
使用实施例1的化合物a(37mg,0.03mmol)和异烟酰氯盐酸盐(5mg,0.03mmol),如实施例2所述进行反应和后处理,从而获得了本标题化合物(1.3mg,4%)。
1H-NMR(CDCl3)δ:1.08(s,3H),1.22(s,3H),1.65(s,3H),1.79(s,3H),1.86(m,1H,C6-H),2.20-2.33(m,2H,C14-H),2.37(s,3H),2.50(s,3H),2.42-2.95(m,5H),3.10(s,1H),3.40-3.85(m,4H),3.76(d,J=7Hz,1H,C3-H),4.17(d,J=9Hz,1H,C20-H),4.29(d ,J=8Hz,1H,C20-H),4.40(m,1H,C7-H),4.78(d,J=3Hz,1H,C2′-H),4.93(d,J=9Hz,1H,C5-H),5.63(d,J=7Hz,1H,C2-H),5.77(dd,J=9,2Hz,1H,C3′-H),6.22(t,J=9Hz,1H,C13-H),6.24(s,1H,C10-H),7.22-7.61(m,11H),8.11(d,J=7Hz,2H),8.68(m,1H).
实施例5
13-O-(3-己酰氨基-2-羟基-3-苯基丙酰基)-10-O-(4-甲基哌嗪-1-基羰基)-10-去乙酰浆果赤霉素III(化合物e)
使用实施例1的化合物a(37mg,0.03mmol)和己酰氯(2.7mg,0.02mmol),如实施例2所述进行反应和后处理,从而获得了本标题化合物(11mg,35%)。
1H-NMR(CDCl3)δ:0.81(t,J=7Hz,3H),1.12(s,3H),1.19-1.27(m,4H),1.50-1.59(m,2H),1.66(s,3H),1.82(s,3H),1.85(m,1H,C6-H),2.17(t,J=7Hz,2H),2.21-2.31(m,2H,C14-H),2.32(s,3H),2.33(s,3H),2.41-2.57(m,5H),3.09(s,1H),3.33-3.75(m,4H),3.76(d,J=7Hz,1H,C3-H),4.17(d,J=8Hz,1H,C20-H),4.27(d,J=8Hz,1H,C20-H),4.41(m,1H,C7-H),4.66(d,J=3Hz,1H,C2′-H),4.93(d,J=8Hz,1H,C5-H),5.56(dd,J=9,3Hz,1H,C3′-H),5.64(d,J=7Hz,1H,C2-H),6.17(d,J=9Hz,1H,NH),6.18(t,J=9Hz,1H,C13-H),6.24(s,1H,C10-H),7.30-7.39(m,5H),7.49(t,J=8Hz,2H),7.59(t,J=7Hz,1H),8.09(d,J=7Hz,2H).
SI-MS m/z:931[M+H]+
实施例6
13-O-(3-异丙氧基羰基氨基-2-羟基-3-苯基丙酰基)-10-O-(4-甲基哌嗪-1-基羰基)-10-去乙酰浆果赤霉素III(化合物f)
使用实施例1的化合物a(71mg,0.06mmol)和氯甲酸异丙酯(7.4mg,0.06mmol),如实施例2所述进行反应和后处理,从而获得了本标题化合物(29mg,50%)。
1H-NMR(CDCl3)δ:1.07(s,3H),1.13(d,J=6Hz,6H),1.24(s,3H),1.65(s,3H),1.84(s,3H),1.86(m,1H,C6-H),2.18-2.26(m,2H,C14-H),2.35(s,3H),2.38-2.65(m,5H),2.39(s,3H),3.09(s,1H),3.40-3.75(m,4H),3.77(d,J=7Hz,1H,C3-H),4.15(d,J=8Hz,1H,C20-H),4.28(d,J=8Hz,1H,C20-H),4.39(m,1H,C7-H),4.62(d,J=2Hz,1H,C2′-H),4.75(m,1H),4.93(d,J=8Hz,1H,C5-H),5.28(br,1H,NH),5.45(dd,J=9,2Hz,1H,C3′-H),5.63(d,J=7Hz,1H,C2-H),6.24(s,1H,C10-H),6.25(t,J=8Hz,1H,C13-H),7.29-7.40(m,5H),7.48(t,J=8Hz,2H),7.59(t,J=7Hz,1H),8.09(d,J=7Hz,2H).
SI-MS m/z:921[M+H]+
实施例7
13-O-(3-苄氧羰基-2,2-二甲基-4-苯基-5-唑烷羰基)-10-O-(4-乙基哌嗪-1-基羰基)-7-O-三乙基甲硅烷基-10-去乙酰浆果赤霉素III(化合物g)
使用10-O-(4-乙基哌嗪-1-基羰基)-7-O-三乙基甲硅烷基-10-去乙酰浆果赤霉素III(200mg,0.25mmol),如实施例1所述进行反应和后处理,从而获得了本标题化合物(268mg,93%)。
1H-NMR(CDCl3)δ:0.56(m,6H),0.90(t,J=8Hz,9H),1.06-1.20(m,9H),1.68(s,3H),1.74(s,3H),1.80(s,3H),1.87(m,1H,C6-H),1.90(s,3H),2.08(s,3H),2.14(d,J=9Hz,2H),2.26-2.80(m,7H),3.40-3.98(m,4H),3.78(d,J=7Hz,1H,C3-H),4.08(d,J=9Hz,1H,C20-H),4.23(d,J=8Hz,1H,C20-H),4.43(dd,J=11,7Hz,1H,C7-H),4.49(d,J=6Hz,1H),4.85-5.12(m,2H),4.86(d,J=8Hz,1H,C5-H),5.22(s,1H),5.63(d,J=7Hz,1H,C2-H),6.21(t,J=9Hz,1H,C13-H),6.36(s,1H,C10-H),6.74(br,1H),7.04-7.33(m,9H),7.46(t,J=8Hz,2H),7.60(t,J=8Hz,1H),8.02(d,J=8Hz,2H).
实施例8
13-O-(3-新戊氧基羰基氨基-2-羟基-3-苯基丙酰基)-10-O-(4-乙基哌嗪-1-基羰基)-10-去乙酰浆果赤霉素III(化合物h)
使用实施例7的化合物g(70mg,0.06mmol)和新戊基对硝基苯基碳酸酯(15mg,0.06mmol),如实施例2所述进行反应和后处理,从而获得了本标题化合物(24mg,41%)。
1H-NMR(CDCl3)δ:0.79(s,9H),1.11(s,3H),1.13(s,3H),1.24(s,3H),1.65(s,3H),1.84(s,3H),1.86(m,1H,C6-H),2.14-2.30(m,2H,C14-H),2.39(s,3H),2.40-2.65(m,7H),3.11(s,1H),3.38-3.76(m,4H),3.59(d,J=10Hz,2H),3.77(d,J=7Hz,1H,C3-H),4.15(d,J=9Hz,1H,C20-H),4.27(d,J=9Hz,1H,C20-H),4.42(m,1H,C7-H),4.64(s,1H,C2′-H),4.93(d,J=8Hz,1H,C5-H),5.31(br,1H,NH),5.54(d,J=9Hz,1H,C3′-H),5.63(d,J=7Hz,1H,C2-H),6.23(s,1H,C10-H),6.24(t,J=9Hz,1H,C13-H),7.31-7.39(m,5H),7.48(t,J=8Hz,2H),7.59(t,J=7Hz,1H),8.10(d,J=7Hz,2H).
SI-MS m/z:962[M+H]+
实施例9
13-O-[3-叔戊氧基羰基氨基-2-羟基-3-苯基丙酰基]-10-O-(4-乙基哌嗪-1-基羰基)-10-去乙酰浆果赤霉素III(化合物i)
使用实施例7的化合物g(54mg,0.05mmol)和二碳酸二叔戊酯(15mg,0.06mmol),如实施例2所述进行反应和后处理,从而获得了本标题化合物(23mg,51%)。
1H-NMR(CDCl3)δ:0.76(t,J=7Hz,3H),1.11(s,3H),1.24(s,3H),1.27(s,6H),1.64-1.68(m,5H),1.85(s,3H),1.86(m,1H,C6-H),2.04-2.30(m,2H,C14-H),2.36(s,3H),2.42-2.61(m,7H),3.27(s,1H),3.35-3.75(m,4H),3.77(d,J=7Hz,1H,C3-H),4.15(d,J=8Hz,1H,C20-H),4.28(d,J=8Hz,1H,C20-H),4.42(m,1H,C7-H),4.61(s,1H,C2′-H),4.94(d,J=9Hz,1H,C5-H),5.26(br,1H,NH),5.34(d,J=10Hz,1H,C3′-H),5.64(d,J=7Hz,1H,C2-H),6.23(m,1H,C13-H),6.25(s,1H,C10-H),7.31-7.41(m,5H),7.48(t,J=8Hz,2H),7.60(t,J=7Hz,1H),8.09(d,J=8Hz,2H).
SI-MS m/z:962[M+H]+
实施例10
13-O-(3-环戊氧基羰基氨基-2-羟基-3-苯基丙酰基)-10-O-(4-乙基哌嗪-1-基羰基)-10-去乙酰浆果赤霉素III(化合物j)
使用实施例7的化合物g(54mg,0.05mmol)和氯甲酸环戊基酯(7mg,0.05mmol),如实施例2所述进行反应和后处理,从而获得了本标题化合物(25mg,55%)。
1H-NMR(CDCl3)δ:1.11(s,3H),1.25(s,3H),1.38-1.75(m,8H),1.65(s,3H),1.83(s,3H),1.85(m,1H,C6-H),2.22-2.30(m,2H,C14-H),2.35(s,3H),2.40-2.65(m,7H),3.30(s,1H),3.35-3.73(m,4H),3.77(d,J=7Hz,1H,C3-H),4.16(d,J=9Hz,1H,C20-H),4.28(d,J=9Hz,1H,C20-H),4.42(m,1H,C7-H),4.62(s,1H,C2′-H),4.90(m,1H),4.93(d,J=7Hz,1H,C5-H),5.28(br,1H,NH),5.41(d,J=9Hz,1H,C3′-H),5.65(d,J=7Hz,1H,C2-H),6.24(m,1H,C13-H),6.25(s,1H,C10-H),7.31-7.40(m,5H),7.48(t,J=8Hz,2H),7.60(t,J=7Hz,1H),8.10(d,J=7Hz,2H).
SI-MS m/z:960[M+H ]+
实施例11
13-O-(3-环己氧基羰基氨基-2-羟基-3-苯基丙酰基)-10-O-(4-乙基哌嗪-1-基羰基)-10-去乙酰浆果赤霉素III(化合物k)
使用实施例7的化合物g(40mg,0.035mmol)和环己基对硝基苯基碳酸酯(13mg,0.05mmol),如实施例2所述进行反应和后处理,从而获得了本标题化合物(3mg,9%)。
1H-NMR(CDCl3)δ:1.02-1.75(m,10H),1.06(s,3H),1.20(s,3H),1.60(s,3H),1.80(s,3H),1.81(m,1H,C6-H),2.17-2.30(m,2H,C14-H),2.33(s,3H),2.42-2.78(m,7H),3.02(s,1H),3.40-3.80(m,4H),3.72(d,J=7Hz,1H,C3-H),4.10(d,J=9Hz,1H,C20-H),4.22(d,J=9Hz,1H,C20-H),4.36(m,1H),4.39(m,1H,C7-H),4.59(s,1H,C2′-H),4.89(d,J=7Hz,1H,C5-H),5.26(d,J=9Hz,1H,NH),5.40(d,J=9Hz,1H,C3′-H),5.58(d,J=7Hz,1H,C2-H),6.20(s,1H,C10-H),6.22(m,1H,C13-H),7.26-7.34(m,5H),7.44(t,J=8Hz,2H),7.55(t,J=7Hz,1H)8.06(d,J=8Hz,2H).
SI-MS m/z:974[M+H]+
实施例12
13-O-(3-苄氧羰基-2,2-二甲基-4-苯基-5-唑烷羰基)-10-O-(4-哌啶子基哌啶子基羰基)-7-O-三乙基甲硅烷基-10-去乙酰浆果赤霉素III(化合物1)
使用10-O-(4-哌啶子基哌啶子基羰基)-7-O-三乙基甲硅烷基-10-去乙酰浆果赤霉素III(120mg,0.14mmol),如实施例1所述进行反应和后处理,从而获得了本标题化合物(161mg,97%)。
1H-NMR(CDCl3)δ:0.56(m,6H),0.89(t,J=8Hz,9H),1.17(s,3H),1.18(s,3H),1.41-2.02(m,11H),1.65(s,3H),1.74(s,3H),1.80(s,3H),1.89(s,3H),2.06(s,3H),2.14(d,J=9Hz,2H),2.40-3.07(m,7H),2.48(m,1H,C6-H),3.77(d,J=7Hz,1H,C3-H),4.08(d,J=9Hz,1H,C20-H),4.23(d,J=9Hz,1H,C20-H),4.30(br,1H),4.43(dd,J=11,7Hz,1H,C7-H),4.49(d,J=6Hz,1H),4.86(d,J=10Hz,1H,C5-H),4.87-5.10(m,2H),5.21(s,1H),5.63(d,J=7Hz,1H,C2-H),6.20(t,J=9Hz,1H,C13-H),6.35(s,1H,C10-H),6.74(br,1H),7.02-7.33(m,9H),7.46(t,J=8Hz,2H),7.60(t,J=8Hz,1H),8.02(d,J=7Hz,2H).
实施例13
13-O-[3-(2-呋喃甲酰氨基)-2-羟基-3-苯基丙酰基)-10-O-(4-哌啶子基哌啶子基羰基)-10-去乙酰浆果赤霉素III(化合物m)
使用实施例12的化合物1(99mg,0.08mmol)和2-呋喃甲酰氯(7.8mg,0.06mmol),如实施例2所述进行反应和后处理,获得本标题化合物(16mg,19%)。
1H-NMR(CDCl3)δ:1.06(s,3H),1.17(s,3H),1.30-1.95(m,11H),1.60(s,3H),1.75(s,3H),2.19-2.27(m,2H,C14-H),2.30(s,3H),2.38-3.10(m,8H),3.51(s,1H),3.72(d,J=7Hz,1H,C3-H),4.12(d,J=9Hz,1H,C20-H),4.23(d,J=9Hz,1H,C20-H),4.09-4.25(m,2H),4.36(m,1H,C7-H),4.70(m,1H,C2′-H),4.89(d,J=8Hz,1H,C5-H),5.59(d,J=7Hz,1H,C2-H),5.68(dd,J=11,3Hz,1H,C3′-H),6.15(m,1H,C13-H),6.16(s,1H,C10-H),6.40(dd,J=4,2Hz,1H),7.95(d,J=3Hz,1H),7.09(d,J=9Hz,1H,NH),7.26-7.42(m,6H),7.45(t,J=8Hz,2H),7.56(t,J=7Hz,1H),8.07(d,J=8Hz,2H).
SI-MS m/z:996[M+H]+
实施例14
13-O-[3-(3-呋喃甲酰氨基)-2-羟基-3-苯基丙酰基)-10-O-(4-哌啶子基哌啶子基羰基)-10-去乙酰浆果赤霉素III(化合物n)
使用实施例12的化合物1(60mg,0.05mmol)和3-呋喃甲酸(7.8mg,0.06mmol)和DCC(0.06mmol),如实施例2所述进行反应和后处理,获得本标题化合物(13mg,26%)。
1H-NMR(CDCl3)δ:1.11(s,3H),1.21(s,3H),1.40-1.98(m,11H),1.64(s,3H),1.79(s,3H),2.23(m,1H,C14-H),2.29(m,1H,C14-H),2.34(s,3H),2.40-3.10(m,8H),3.16(s,1H),3.76(d,J=7Hz,1H,C3-H),4.09-4.27(m,2H),4.16(d,J=8Hz,1H,C20-H),4.26(d,J=9Hz,1H,C20-H),4.40(m,1H,C7-H),4.74(m,1H,C2′-H),4.92(d,J=9Hz,1H,C5-H),5.63(d,J=7Hz,1H,C2-H),5.72(d,J=9Hz,1H,C3′-H),6.21(s,1H,C10-H),6.23(m,1H,C13-H),6.58(s,1H),6.77(d,J=9Hz,1H,NH),7.29-7.44(m,6H),7.49(t,J=8Hz,2H),7.60(t,J=7Hz,1H),7.88(m,1H),8.10(d,J=8Hz,2H).
SI-MS m/z:996[M+H]+
实施例15
13-O-(3-苄氧羰基-2,2-二甲基-4-苯基-5-唑烷羰基)-10-O-(4-二丙基氨基哌啶子基羰基)-7-O-三乙基甲硅烷基-10-去乙酰浆果赤霉素III(化合物o)
使用10-O-(4-二丙基氨基哌啶子基羰基)-7-O-三乙基甲硅烷基-10-去乙酰浆果赤霉素III(710mg,0.82mmol),如实施例1所述进行反应和后处理,获得本标题化合物(760mg,77%)。
1H-NMR(CDCl3)δ:0.56(m,6H),0.90(t,J=7Hz,9H),0.92-1.02(m,6H),1.16(s,3H),1.17(s,3H),1.24-1.96(m,9H),1.63(s,3H),1.74(s,3H),1.80(s,3H),1.89(s,3H),2.00-3.14(m,10H),2.08(s,3H),3.78(d,J=8Hz,1H,C3-H),4.08(d,J=8Hz,1H,C20-H),4.18-4.58(m,4H),4.22(d,J=8Hz,1H,C20-H),4.86(d,J=9Hz,1H,C5-H),4.85-5.10(m,2H),5.20(s,1H),5.62(d,J=7Hz,1H,C2-H),6.21(m,1H,C13-H),6.36(s,1H,C10-H),6.68(br,1H),7.05-7.50(m,9H),7.46(t,J=8Hz,2H),7.60(t,J=7Hz,1H),8.02(d,J=8Hz,2H).
实施例16
13-O-(3-新戊氧基羰基氨基-2-羟基-3-苯基丙酰基)-10-O-(4-二丙基氨基哌啶子基羰基)-10-去乙酰浆果赤霉素III(化合物p)
使用实施例15的化合物o(76mg,0.06mmol)和新戊基对硝基苯基碳酸酯(15mg,0.06mmol),如实施例2所述进行反应和后处理,获得本标题化合物(28mg,43%)。
1H-NMR(CDCl3)δ:0.75(s,9H),0.76-0.94(m,6H),1.07(s,3H),1.19(s,3H),1.30-1.98(m,6H),1.60(s,3H),1.82(s,3H),2.09-3.15(m,10H),2.31(s,3H),3.30(br,1H),3.54(d,J=10Hz,1H),3.64(d,J=10Hz,1H),3.72(d,J=7Hz,1H,C3-H),4.05-4.23(m,2H),4.11(d,J=8Hz,1H,C20-H),4.22(d,J=8Hz,1H,C20-H),4.37(m,1H,C7-H),4.60(s,1H,C2′-H),4.89(d,J=8Hz,1H,C5-H),5.26(br,1H,NH),5.48(br,1H,C3′-H),5.58(d,J=7Hz,1H,C2-H),6.18(s,1H,C10-H),6.20(t,J=9Hz,1H,C13-H),7.27-7.34(m,5H),7.43(t,J=8Hz,2H),7.54(t,J=7Hz,1H),8.05(d,J=7Hz,2H).
SI-MS m/2:1032[M+H]+
实施例17
13-O-[3-叔戊氧基羰基氨基-2-羟基-3-苯基丙酰基]-10-O-(4-二丙基氨基哌啶子基羰基)-10-去乙酰浆果赤霉素III(化合物q)
使用实施例15的化合物o(76mg,0.06mmol)和二碳酸二叔戊酯(15mg,0.06mmol),如实施例2所述进行反应和后处理,获得本标题化合物(23mg,36%)。
1H-NMR(CDCl3)δ:0.76(m,3H),0.83-0.94(m,6H),1.12(s,3H),1.25(s,3H),1.27(s,6H),1.36-1.96(m,11H),1.65(s,3H),1.84(s,3H),2.08-3.08(m,10H),2.35(s,3H),3.17(s,1H),3.77(d,J=7Hz,1H,C3-H),4.12-4.30(m,2H),4.15(d,J=8Hz,1H,C20-H),4.27(d,J=8Hz,1H,C20-H),4.42(m,1H,C7-H),4.61(s,1H,C2′-H),4.94(d,8Hz,1H,C5-H),5.26(br,1H,NH),5.36(d,J=10Hz,1H,C3′-H),5.64(d,J=7Hz,1H,C2-H),6.23(s,1H,C10-H),6.24(t,J=9Hz,1H,C13-H),7.28-7.40(m,5H),7.48(t,J=8Hz,2H),7.59(t,J=7Hz,1H),8.09(d,J=7Hz,2H).
SI-MS m/z:1032[M+H]+
测试1
新的水溶性紫杉烷衍生物的溶解度
I)测定化合物(b)的溶解度
1)测定校正曲线
称重1.19mg化合物(b),向其中加入1.19ml乙腈,使该化合物溶解作为标准溶液。使用10μl该标准溶液,通过HPLC(操作条件1)进行测试。通过自动积分来计量由标准溶液的色谱图获得的化合物(b)的峰面积。将所得峰面积(3次测试的平均值)对每10μl中化合物(b)的量(10.0μg)作图,由此制得了校正曲线。
校正曲线:Y=2.08×10-5X[X:峰面积,Y:化合物(b)的量(μg)]
[HPLC操作条件1]
柱:Inertsil ODS-2(5-250),40deg。
流动相:0.01M KH2PO4-CH3CN(3∶2)
流速:1.0ml/分钟。
检测:紫外吸收光度计(225nm),0.2满刻度吸光度单位。
2)化合物(b)的溶解度测试:
称重4.0mg化合物(b),然后悬浮在2.0ml纯化水中。将45μl(1.05当量)0.1N的盐酸加到所得悬浮液中。通过超声处理将所得混合物形成均匀悬浮液,然后在室温振摇2小时。通过膜滤器(0.22μm)过滤所得混合物,以滤液作为测试溶液。使用所得测试溶液,通过HPLC(操作条件1)进行所述测试。由所得面积(3次测试平均值)测定化合物(b)的溶解度。
所得化合物(b)的面积(X)(3次测试平均值):478747
化合物(b)溶解的量(Y):9.98μg/5μl(2.00mg/ml)
I)测定化合物(j)的溶解度
1)测定校正曲线
称重0.94mg化合物(j),向其中加入0.94ml乙腈,使该化合物溶解以提供标准溶液。使用10μl该标准溶液,通过HPLC(操作条件1)进行测试。通过自动积分来计量由标准溶液的色谱图获得的化合物(j)的峰面积。将作为3次测试平均值的所得峰面积对每10μl中化合物(j)的量(10.0μg)作图,由此制得了校正曲线。
校正曲线:Y=2.02×10-5X[X:峰面积,Y:化合物(j)的量(μg)]
[HPLC操作条件1]
柱:Inertsil ODS-2(5-250),40deg。
流动相:0.01M KH2PO4-CH3CN(3∶2)
流速:1.0ml/分钟。
检测:紫外吸收光度计(225nm),0.2满刻度吸光单位。
2)化合物(j)的溶解度测试:
称重4.24mg化合物(j),然后悬浮在2.0ml纯化水中。将46μl(1.05当量)0.1N的盐酸加到所得悬浮液中。通过超声处理将所得混合物形成均匀悬浮液,然后在室温振摇2小时。通过膜滤器(0.22μm)过滤所得混合物,以滤液作为测试溶液。使用所得测试溶液,通过HPLC(操作条件1)进行所述测试。由作为3次测试的平均值的所得面积测定化合物(j)的溶解度。
获得的作为3次测试平均值的化合物(j)的面积(X):456054化合物(j)溶解的量(Y):9.20μg/5μl(1.84mg/ml)
将上述结果和紫杉醇的溶解度列入表1中进行比较。从表1中可知,本发明化合物在水中有很高的溶解度。
表1
化合物 | 溶解度(μg/ml) |
紫杉醇 | 0.4 |
化合物b | 2000 |
化合物j | 1840 |
测试2
癌细胞增殖活性:
材料和方法
细胞
使用来自人口腔癌细胞的KB细胞,所用KB细胞是从DainipponPharmaceutical Co.,Ltd.购买的,并以冷冻干燥的形式贮藏在该公司的研究所内。在含有10%胎牛血清的Dulbecco改进的Eagle培养基(NISSUI制药有限公司的产品)中培养KB细胞,并维持在5%CO2-空气和37℃条件下。
药物
将使用的每一种药物都以10mg/ml的浓度溶解在DMSO中。
药物处理
(1)KB
在第1天,用含有10%胎牛血清的不含酚红的培养基(Dulbecco改进的Eagle培养基(Sigma)),将处于对数生长期的细胞以2000个细胞/100μl/孔的量接种到96孔微量滴定板(Falcon#3072)上,过夜培养。在第0天,将各自用相同培养基稀释至0.03-10000ng/ml的化合物以100μl等分试样的量加到各个孔中,将细胞培养3天。每一药物浓度使用3个孔。对于每一块板,提供3个仅含有培养基的空白孔,并提供8个孔作为未用药物处理的对照组。
XTT分析
使用XTT(Sigma),将其以1mg/ml的浓度溶于不含血清的每一培养基中。将以5mM浓度溶于PBS的甲磺酸苏木精以1/200的体积比加到所得溶液中。将制得的溶液以50μl/孔的量加到每个孔中。培养4小时后,通过ELISA在450nm测定OD。
计算50%生长抑制浓度(GI
50
)
通过内推法由浓度-生长抑制比率(GIR)计算GI50。依据下述公式确定GIR:
GIR=100-[OD处理(第3天)-OD对照(第0天)]/[OD对照(第3天)-OD对照(第0天)]×100测试结果如表2所示。
表2
KB | ||
GI<sub>50</sub>(ng/ml) | 活性比例 | |
紫杉醇bj | 1.31.40.58 | 1.00.92.2 |
工业实用性
本发明紫杉烷衍生物在水中有很高的溶解度,即其水溶解度是紫杉醇的1000倍或1000倍以上,因此无需使用特殊溶剂就能配制成液体制剂例如注射剂。此外,本发明紫杉烷衍生物还具有优良的抗肿瘤活性。
Claims (3)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP9251804A JPH1192468A (ja) | 1997-09-17 | 1997-09-17 | 新規なタキサン誘導体 |
JP251804/1997 | 1997-09-17 | ||
JP251804/97 | 1997-09-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1270587A CN1270587A (zh) | 2000-10-18 |
CN100369908C true CN100369908C (zh) | 2008-02-20 |
Family
ID=17228181
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB988092395A Expired - Fee Related CN100369908C (zh) | 1997-09-17 | 1998-09-17 | 紫杉烷衍生物 |
Country Status (14)
Country | Link |
---|---|
US (1) | US6136808A (zh) |
EP (1) | EP1022277B1 (zh) |
JP (1) | JPH1192468A (zh) |
KR (1) | KR100514809B1 (zh) |
CN (1) | CN100369908C (zh) |
AT (1) | ATE229012T1 (zh) |
AU (1) | AU730174B2 (zh) |
BR (1) | BR9812218A (zh) |
CA (1) | CA2302445C (zh) |
DE (1) | DE69809959T2 (zh) |
DK (1) | DK1022277T3 (zh) |
ES (1) | ES2189234T3 (zh) |
PT (1) | PT1022277E (zh) |
WO (1) | WO1999014209A1 (zh) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100551945B1 (ko) * | 1997-12-19 | 2006-02-20 | 가부시키가이샤 야쿠루트 혼샤 | 택산 유도체 |
DE60031269T2 (de) * | 1999-05-28 | 2007-05-31 | Bristol-Myers Squibb Co. | Halbsynthese von paclitaxel mit hilfe von dialkyldichlorsilanen |
KR20010111580A (ko) * | 2000-02-02 | 2001-12-19 | 플로리다 스테이트 유니버시티 리서치 파운데이션, 인크 | 개선된 용해도를 갖는 탁산 제형물 |
JP2003522173A (ja) | 2000-02-02 | 2003-07-22 | フロリダ・ステイト・ユニバーシティ・リサーチ・ファウンデイション・インコーポレイテッド | 抗腫瘍剤としてのc10カルバモイルオキシ置換タキサン |
US6649632B2 (en) * | 2000-02-02 | 2003-11-18 | Fsu Research Foundation, Inc. | C10 ester substituted taxanes |
US6656966B2 (en) | 2000-06-22 | 2003-12-02 | Nitromed, Inc. | Nitrosated and nitrosylated taxanes, compositions and methods of use |
CA2354471A1 (en) * | 2001-07-31 | 2003-01-31 | Florida State University Research Foundation, Inc. | C10 ester substituted taxanes |
US7351542B2 (en) | 2002-05-20 | 2008-04-01 | The Regents Of The University Of California | Methods of modulating tubulin deacetylase activity |
DE60329497D1 (de) | 2002-06-26 | 2009-11-12 | Medigene Ag | Herstellung einer kationisch liposomalen zubereitung, einen lipophilen wirkstoff enthaltend |
EP2390262A1 (en) | 2003-05-16 | 2011-11-30 | Intermune, Inc. | Synthetic chemokine receptor ligands and methods of use thereof |
HN2005000054A (es) | 2004-02-13 | 2009-02-18 | Florida State University Foundation Inc | Taxanos sustituidos con esteres de ciclopentilo en c10 |
PE20061090A1 (es) * | 2005-02-14 | 2006-10-12 | Univ Florida State Res Found | Preparaciones de taxanos sustituidos con esteres de ciclopropilo en c10 |
JP4954983B2 (ja) | 2005-05-18 | 2012-06-20 | ファーマサイエンス・インコーポレイテッド | Birドメイン結合化合物 |
CA2646156C (en) | 2006-03-22 | 2016-05-24 | Medigene Ag | Treatment of triple receptor negative breast cancer |
CN101535300B (zh) | 2006-05-16 | 2014-05-28 | 埃格拉医疗公司 | Iap bir域结合化合物 |
KR100847331B1 (ko) * | 2006-12-14 | 2008-07-21 | 한미약품 주식회사 | 도세탁셀의 제조방법 및 이에 사용되는 중간체 |
JP2011517455A (ja) * | 2008-03-31 | 2011-06-09 | フロリダ・ステイト・ユニバーシティ・リサーチ・ファウンデイション・インコーポレイテッド | C(10)エチルエステルおよびc(10)シクロプロピルエステル置換タキサン |
EP2859916B1 (en) | 2008-05-22 | 2017-11-29 | Galera Labs, LLC | Combination of an antimitotic agent and a selective superoxide dismutase mimetic in antitumor therapy |
KR20170127069A (ko) * | 2008-06-16 | 2017-11-20 | 화이자 인코포레이티드 | 약물 부하된 중합체성 나노입자, 및 이의 제조 및 사용 방법 |
EP2310507A4 (en) | 2008-07-08 | 2013-03-20 | David Gladstone Inst | METHODS AND COMPOSITIONS FOR MODULATING ANGIOGENESIS |
KR101014438B1 (ko) * | 2008-09-26 | 2011-02-14 | 동아제약주식회사 | 탁산 유도체의 제조방법 |
SG182724A1 (en) | 2010-02-12 | 2012-08-30 | Pharmascience Inc | Iap bir domain binding compounds |
US9532972B2 (en) | 2012-02-07 | 2017-01-03 | University Of Central Florida Research Foundation, Inc. | Increasing taxane sensitivity in cancer cells |
CN104582717B (zh) | 2012-07-19 | 2018-03-13 | 雷德伍德生物科技股份有限公司 | 对cd22有特异性的抗体及其使用方法 |
WO2014074218A1 (en) | 2012-11-12 | 2014-05-15 | Redwood Bioscience, Inc. | Compounds and methods for producing a conjugate |
EP3300745B9 (en) | 2013-02-15 | 2020-04-15 | The Regents of the University of California | Chimeric antigen receptor and methods of use thereof |
EP2970124B1 (en) | 2013-03-14 | 2019-05-22 | The Board of Trustees of the Leland Stanford Junior University | Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof |
WO2015081282A1 (en) | 2013-11-27 | 2015-06-04 | Redwood Bioscience, Inc. | Hydrazinyl-pyrrolo compounds and methods for producing a conjugate |
HUE051255T2 (hu) | 2014-02-19 | 2021-03-01 | Aviv Therapeutics Inc | Mitokondriális aldehid dehidrogenáz 2 (ALDH2) kötõ policiklusos amidok és alkalmazásuk rák kezelésére |
EP3126006A1 (en) | 2014-03-21 | 2017-02-08 | AbbVie Inc. | Anti-egfr antibodies and antibody drug conjugates |
US10300070B2 (en) | 2014-03-27 | 2019-05-28 | The Brigham And Women's Hospital, Inc. | Metabolically-activated drug conjugates to overcome resistance in cancer therapy |
EP3373977A4 (en) | 2015-11-12 | 2019-07-17 | The Board of Trustees of the Leland Stanford Junior University | CELLULAR PENETRATION-RICH GUANIDINIC OLIGOPHOSPHOTRIESTERS FOR THE DELIVERY OF MEDICATION AND PROBE |
TWI760319B (zh) | 2015-12-30 | 2022-04-11 | 杏國新藥股份有限公司 | 乳癌治療 |
EP3231421A1 (en) | 2016-04-11 | 2017-10-18 | Greenaltech, S.L. | Uses of a carotenoid in the treatment or prevention of stress induced conditions |
WO2017189432A1 (en) | 2016-04-26 | 2017-11-02 | R.P. Scherer Technologies, Llc | Antibody conjugates and methods of making and using the same |
SI3463308T1 (sl) | 2016-06-01 | 2022-04-29 | Servier IP UK Limited | Formulacije polialkilenoksidne asparaginaze in postopki za pripravo in uporabo le-teh |
JP2019522643A (ja) | 2016-06-08 | 2019-08-15 | アッヴィ・インコーポレイテッド | 抗cd98抗体及び抗体薬物コンジュゲート |
EP3468993A1 (en) | 2016-06-08 | 2019-04-17 | AbbVie Inc. | Anti-b7-h3 antibodies and antibody drug conjugates |
BR112018075649A2 (pt) | 2016-06-08 | 2019-04-09 | Abbvie Inc. | anticorpos anti-b7-h3 e conjugados de fármaco de anticorpo |
US20200002432A1 (en) | 2016-06-08 | 2020-01-02 | Abbvie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
CN116284404A (zh) | 2016-06-08 | 2023-06-23 | 艾伯维公司 | 抗b7-h3抗体和抗体药物偶联物 |
TW201825087A (zh) | 2017-01-05 | 2018-07-16 | 杏國新藥股份有限公司 | 胰臟癌治療 |
AU2018211081A1 (en) | 2017-01-18 | 2019-07-18 | Bioatla, Inc. | Chimeric antigen receptors against Axl or Ror2 and methods of use thereof |
EP3388082A1 (en) | 2017-04-13 | 2018-10-17 | Galera Labs, LLC | Combination cancer immunotherapy with pentaaza macrocyclic ring complex |
MX2021000644A (es) | 2018-07-18 | 2021-08-19 | Manzanita Pharmaceuticals Inc | Conjugados para suministrar un agente contra el cancer a las celulas nerviosas, metodos de uso y metodos para la elaboracion de los mismos. |
WO2020206033A1 (en) | 2019-04-02 | 2020-10-08 | Kenjockety Biotechnology, Inc. | Efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto |
JP2023512196A (ja) | 2020-01-29 | 2023-03-24 | ケンジョッケティ バイオテクノロジー,インク. | 抗mdr1抗体およびその使用 |
CA3182472A1 (en) | 2020-06-04 | 2021-12-09 | Kenjockety Biotechnology, Inc. | Anti-abcg2 antibodies and uses thereof |
JP2023528417A (ja) | 2020-06-04 | 2023-07-04 | ケンジョッケティ バイオテクノロジー,インク. | Abcg2排出ポンプ-がん抗原多重特異性抗体並びにそれらに関連する組成物、試薬、キット、及び方法 |
EP4208483A1 (en) | 2020-09-02 | 2023-07-12 | Kenjockety Biotechnology, Inc. | Anti-abcc1 antibodies and uses thereof |
WO2022103603A1 (en) | 2020-11-13 | 2022-05-19 | Kenjockety Biotechnology, Inc. | Anti-mrp4 (encoded by abcc4 gene) antibodies and uses thereof |
AR124681A1 (es) | 2021-01-20 | 2023-04-26 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
WO2023114658A1 (en) | 2021-12-13 | 2023-06-22 | Kenjockety Biotechnology, Inc. | Anti-abcb1 antibodies |
WO2023159220A1 (en) | 2022-02-18 | 2023-08-24 | Kenjockety Biotechnology, Inc. | Anti-cd47 antibodies |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0406274A1 (en) * | 1988-03-07 | 1991-01-09 | Us Health | WATER-SOLUBLE TAXOL ANTINEOPLASTIC DERIVATIVES. |
EP0534709A1 (en) * | 1991-09-23 | 1993-03-31 | Florida State University | Substituted taxanes as antitumour agents |
EP0625148A1 (fr) * | 1992-02-07 | 1994-11-23 | Aventis Pharma S.A. | Nouveaux derives de la baccatine iii et de la desacetyl-10 baccatine iii, leur preparation et les compositions pharmaceutiques qui les contiennent |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5227400A (en) * | 1991-09-23 | 1993-07-13 | Florida State University | Furyl and thienyl substituted taxanes and pharmaceutical compositions containing them |
US5243045A (en) * | 1991-09-23 | 1993-09-07 | Florida State University | Certain alkoxy substituted taxanes and pharmaceutical compositions containing them |
JPH08253465A (ja) * | 1995-03-17 | 1996-10-01 | Dai Ichi Seiyaku Co Ltd | 四環性化合物 |
FR2742753B1 (fr) * | 1995-12-22 | 1998-01-30 | Rhone Poulenc Rorer Sa | Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent |
BR9710366A (pt) * | 1996-07-15 | 1999-08-17 | Yakult Honsha Kk | Derivados de taxane e drogas que os contêm |
US6017935A (en) * | 1997-04-24 | 2000-01-25 | Bristol-Myers Squibb Company | 7-sulfur substituted paclitaxels |
-
1997
- 1997-09-17 JP JP9251804A patent/JPH1192468A/ja active Pending
-
1998
- 1998-09-17 KR KR10-2000-7002637A patent/KR100514809B1/ko not_active IP Right Cessation
- 1998-09-17 DK DK98943019T patent/DK1022277T3/da active
- 1998-09-17 BR BR9812218-5A patent/BR9812218A/pt not_active Application Discontinuation
- 1998-09-17 CA CA002302445A patent/CA2302445C/en not_active Expired - Fee Related
- 1998-09-17 CN CNB988092395A patent/CN100369908C/zh not_active Expired - Fee Related
- 1998-09-17 EP EP98943019A patent/EP1022277B1/en not_active Expired - Lifetime
- 1998-09-17 PT PT98943019T patent/PT1022277E/pt unknown
- 1998-09-17 US US09/508,092 patent/US6136808A/en not_active Expired - Fee Related
- 1998-09-17 ES ES98943019T patent/ES2189234T3/es not_active Expired - Lifetime
- 1998-09-17 AT AT98943019T patent/ATE229012T1/de not_active IP Right Cessation
- 1998-09-17 WO PCT/JP1998/004180 patent/WO1999014209A1/ja active IP Right Grant
- 1998-09-17 AU AU90950/98A patent/AU730174B2/en not_active Ceased
- 1998-09-17 DE DE69809959T patent/DE69809959T2/de not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0406274A1 (en) * | 1988-03-07 | 1991-01-09 | Us Health | WATER-SOLUBLE TAXOL ANTINEOPLASTIC DERIVATIVES. |
EP0534709A1 (en) * | 1991-09-23 | 1993-03-31 | Florida State University | Substituted taxanes as antitumour agents |
EP0625148A1 (fr) * | 1992-02-07 | 1994-11-23 | Aventis Pharma S.A. | Nouveaux derives de la baccatine iii et de la desacetyl-10 baccatine iii, leur preparation et les compositions pharmaceutiques qui les contiennent |
Also Published As
Publication number | Publication date |
---|---|
US6136808A (en) | 2000-10-24 |
EP1022277A4 (en) | 2000-07-26 |
ES2189234T3 (es) | 2003-07-01 |
EP1022277B1 (en) | 2002-12-04 |
CA2302445C (en) | 2008-04-29 |
KR20010023937A (ko) | 2001-03-26 |
DK1022277T3 (da) | 2003-01-06 |
DE69809959D1 (de) | 2003-01-16 |
JPH1192468A (ja) | 1999-04-06 |
EP1022277A1 (en) | 2000-07-26 |
AU9095098A (en) | 1999-04-05 |
BR9812218A (pt) | 2000-07-18 |
PT1022277E (pt) | 2003-04-30 |
KR100514809B1 (ko) | 2005-09-13 |
WO1999014209A1 (fr) | 1999-03-25 |
CA2302445A1 (en) | 1999-03-25 |
ATE229012T1 (de) | 2002-12-15 |
CN1270587A (zh) | 2000-10-18 |
AU730174B2 (en) | 2001-03-01 |
DE69809959T2 (de) | 2003-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100369908C (zh) | 紫杉烷衍生物 | |
CN101405294B (zh) | 用于酶抑制的化合物 | |
CA2337857C (en) | Calcium (3s) tetrahydro-3-furanyl(1s,2r)-3-[[(4-aminophenyl) sulfonyl](isobutyl)amino]-1-benzyl-2-(phosphonooxy)propylcarbamate | |
CN111848544B (zh) | 可荧光示踪的氨基酸衍生物及其制备方法和应用 | |
CN102659630A (zh) | 一种异羟肟酸类化合物及其制备方法和用途 | |
CN114555607B (zh) | 一类靶向蛋白质水解通路的功能分子及其制备和应用 | |
CN104945470A (zh) | 杂环构建的三肽环氧酮类化合物及制备和应用 | |
AU1682299A (en) | Taxane derivatives | |
CN108129366B (zh) | 抗病毒化合物、制备方法及其用途 | |
CN108456239A (zh) | 具有抗肿瘤作用的化合物ba-x及其制备方法和应用 | |
JPS63275575A (ja) | ピペラジン誘導体 | |
CN100354253C (zh) | 一类5,8-二氢萘醌衍生物、其制备方法和用途 | |
CN103491777B (zh) | 组织蛋白酶c抑制剂 | |
CN115141206B (zh) | 一种ɑ-硫辛酸石蒜碱偶联物及其制备方法和应用 | |
WO2017051761A1 (ja) | 新規なプロドラッグ | |
CN101293830B (zh) | 1-氧-[3-芳基取代-烯丙酰]奎尼酸类化合物及用途 | |
CN116041349B (zh) | 一种黄嘌呤类化合物及其制备方法和在制备新冠病毒3cl蛋白酶抑制剂中的应用 | |
CN115417877B (zh) | 组蛋白去乙酰化酶抑制剂及其制备和在制备抗癌症药物上的应用 | |
CN101215276B (zh) | N,n’-取代苯丙氨基酸苯丙氨基醇酯类衍生物及其制备方法 | |
EP0933373B1 (en) | Terpenoid lactone compounds and their production process | |
CN1319970C (zh) | 一种用作抗肿瘤剂的喜树碱衍生物及其制备方法 | |
CN115626894A (zh) | 一种具有镇痛活性的高乌甲素衍生物及其制备方法和应用 | |
CN1335305A (zh) | 新颖的有n-取代的硫代氨基甲酰基的氨基甲酸酯化合物及其制备方法 | |
JPH06107546A (ja) | Adm耐性解除剤 | |
JPH10158163A (ja) | 消化管障害軽減剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080220 Termination date: 20091019 |